On March 22, 2010, the U.S.
Food and Drug Administration (FDA) recommended suspending the use of
Rotarix, one of two vaccines licensed in the United States against
rotavirus, due to findings of viral
DNA contamination. Follow-up work by
GlaxoSmithKline confirmed the contamination in working cells and the viral "seed" used in Rotarix production, also confirming the material was likely present since the early stages of product development, including the
clinical trials for FDA approval. Testing of the other licensed vaccine against rotavirus infection,
RotaTeq, also detected some components of both PCV-1 and PCV-2. Porcine circovirus 1 is not known to cause disease in humans or other animals. ==See also==